《公司业绩》荣昌生物-B(09995.HK)全年亏损扩大至6.98亿元
荣昌生物-B(09995.HK)公布截至去年12月底止全年业绩,亏损扩大至6.98亿元人民币(下同),上年同期蚀4.3亿元;每股亏损1.45元。不派息。
期内,研发开支按年增加约32%至4.66亿元。
公司指,今年会致力将泰它西普和disitamab vedotin在中国获批上市并成功商业化。同时,会加速推进这两款产品适应症拓展的申报和临床试验工作。其中,预计会在第三季度在中国向NMPA申报disitamab vedotin就治疗UC适应症的NDA。另外,尽快推进泰它西普的其他几个自身免疫疾病适应症的临床试验工作。
国际方面,会加大在国际市场,尤其是美国和欧洲的拓展力度,快速推进并启动两个核心产品在国际市场的临床研究。预计今年下半年在美国启动泰它西普治疗SLE适应症的III期临床试验以及治疗IgA肾病的II期临床试验,同时也计划在美国启动disitamabvedotin就二线治疗HER2过表达UC适应症的II期临床试验。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.